The effects of transport temperature and time on routine and specialized coagulation assays

被引:15
|
作者
Kim, Yeowon A. [1 ]
Lewandrowski, Kent B. [1 ]
Lucien, Fils-Amie [1 ]
Van Cott, Elizabeth M. [1 ]
机构
[1] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA
关键词
coagulation tests; ice; quality assurance; room temperature; specimen stability; WHOLE-BLOOD; INR;
D O I
10.1097/MBC.0000000000000700
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Coagulation laboratories have largely stopped transporting whole blood specimens on ice, due to adverse effects on factor VIII, von Willebrand factor, and the prothrombin time. However, it is unknown whether ice should be required or avoided for other coagulation assays. Furthermore, the amount of time that specimens remain stable during transportation at room temperature (RT) is also largely unknown for many coagulation tests. Therefore, this study investigated specimen stability on ice and RT for a comprehensive panel of coagulation tests. One tube of whole blood from each volunteer (nU22) was centrifuged immediately (time 0), one was stored for 4 h on ice, and one was stored for 4 h at RT before centrifugation. Among time 0, 4 h on ice, and 4 h at RT samples, no statistically significant differences were found for fibrinogen, activated protein C resistance, thrombin time, reptilase time, antithrombin activity, chromogenic protein C, factor XII, and antiplasmin activity. Prothrombin time, activated partial thromboplastin time, factors IX, XI, protein S activity, and plasminogen activity showed statistically, but not clinically, significant differences. On ice, the only analytes that showed clinically significant changes (>= 6.0% from time 0) were factors VII, VIII, von Willebrand factor antigen, and ristocetin cofactor, which were 14.0% higher, and 19.2, 9.5, and 18.8% lower than time 0, respectively. At RT, all analytes were stable except factor VIII was 9.4% lower than time 0. Only factors II, V, X, and PTT-LA lupus anticoagulant showed a possible slight benefit from ice, but the statistically significant differences were not clinically significant. Ice did not substantially benefit any of the coagulation assays. All tests were stable at RT, except more study is needed regarding factor VIII. Copyright (C) 2018 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:184 / 188
页数:5
相关论文
共 50 条
  • [21] BETRIXABAN: IMPACT ON ROUTINE AND SPECIFIC COAGULATION ASSAYS - PRACTICAL LABORATORY GUIDANCE
    Siriez, Romain
    Evrard, Jonathan
    Dogne, Jean-Michel
    Pochet, Lionel
    Gheldof, Damien
    Chatelain, Bernard
    Vancraeynest, Christelle
    Devel, Philippe
    Guldenpfennig, Maite
    Devroye, Celia
    Mullier, Francois
    Douxfils, Jonathan
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2018, 40 : 137 - 137
  • [22] Effect of Centrifuge Temperature on Routine Coagulation Tests
    Yazar, Hayrullah
    Ozdemir, Fatma
    Kose, Elif
    ACTA HAEMATOLOGICA, 2018, 139 (03) : 158 - 163
  • [23] Dabigatran assessment in patients with acute complications using routine coagulation assays
    Stang, Linda
    Nahirniak, Susan
    Butcher, Ken
    Szkotak, Artur J.
    BLOOD COAGULATION & FIBRINOLYSIS, 2014, 25 (05) : 426 - 434
  • [24] Edoxaban: Impact on routine and specific coagulation assays A practical laboratory guide
    Douxfils, Jonathan
    Chatelain, Bernard
    Chatelain, Christian
    Dogne, Jean-Michel
    Mullier, Francois
    THROMBOSIS AND HAEMOSTASIS, 2016, 115 (02) : 368 - 381
  • [25] Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide
    Douxfils, Jonathan
    Chatelain, Christian
    Chatelain, Bernard
    Dogne, Jean-Michel
    Muller, Francois
    THROMBOSIS AND HAEMOSTASIS, 2013, 110 (02) : 283 - 294
  • [26] Impact of edoxaban on a large panel of routine of more specific coagulation assays
    Douxfils, J.
    Bianco, T. D.
    Baudar, J.
    Lessire, S.
    Chatelain, B.
    Dogne, J-M
    Mullier, F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 297 - 297
  • [27] Influence of dabigatran and rivaroxaban on routine coagulation assays A nationwide Belgian survey
    Van Blerk, Marjan
    Bailleul, Els
    Chatelain, Bernard
    Demulder, Anne
    Devreese, Katrien
    Douxfils, Jonathan
    Jochmans, Kristin
    Mullier, Francois
    Wijns, Walter
    Soumali, Mohamed Rida
    Coucke, Wim
    Vernelen, Kris
    Van de Walle, Philippe
    THROMBOSIS AND HAEMOSTASIS, 2015, 113 (01) : 154 - 164
  • [28] The effects of apixaban on routine coagulation tests including prothrombin time and activated partial thromboplastin time
    Lowe, A.
    Hickey, K.
    Maclean, R.
    van Veen, J.
    Kitchen, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 : 21 - 21
  • [29] Reference Intervals of Routine Coagulation Assays During the Pregnancy and Puerperium Period
    Gong, Jiao-Mei
    Shen, Yong
    He, Yan-Xia
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2016, 30 (06) : 912 - 917
  • [30] Interference in specialized coagulation assays affecting the protein C pathway: Effects of marked haemolysis, hyperbilirubinaemia and lipaemia on chromogenic and clotting tests on two coagulation platforms
    Jilma-Stohiawetz, Petra
    Lysy, Katharina
    Belik, Sabine
    Jilma, Bernd
    Quehenberger, Peter
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2019, 41 (03) : 404 - 411